The death of a six-year-old girl after receiving an experimental gene-editing therapy has been described by scientists as a tragedy that highlights the need to improve trial safeguards. But some in the biotechnology industry fear Chinese policymakers may curtail the regulatory flexibility that scientists have long enjoyed in initiating clinical trials – a key mechanism behind China’s competitive edge in frontier treatments. “I hope this tragedy does not have a lasting negative impact on...
China’s emergence as a global biotechnology innovation hub has become a source of strategic concern in the United States, prompting policymakers in Washington to re-evaluate how to respond to its growing influence, according to a recent report by a leading analytics firm. “The country’s latest biotechnology success is strategically important, with implications extending beyond healthcare innovation to include pharmaceutical supply-chain resilience, economic competitiveness and national...
A US-headquartered biotech firm plans to seek a primary listing in Hong Kong, joining a swelling pipeline of artificial intelligence-powered medical players raising capital in the city. Axiom Biosciences, which develops experimental therapies for newborns with severe brain injuries by using AI, is targeting at least US$200 million through an initial public offering (IPO) in Hong Kong in 2027, followed by a secondary listing in the US in 2029. “Some of the most important science in the world is...
The first phase of Hong Kong’s Hetao innovation hub, a key cross-border initiative under the Northern Metropolis megaproject, has been well received, with two of its wet laboratory buildings fully leased, its chairman has revealed. Permanent Secretary for Innovation, Technology and Industry Kevin Choi Kit-ming, who also chairs the Hong Kong-Shenzhen Innovation and Technology Park in the Lok Ma Chau Loop, said on Saturday that more than half of the tenant companies were from mainland China. “As...